- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 496
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 337 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 1,385
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myeloma
- Interventions
- Lenalidomide, Bortezomib, Siltuximab, Dexamethasone, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,095 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2037
- U.S. locations
- 58
- States / cities
- Fresno, California • San Diego, California • Santa Barbara, California + 48 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 13
- States / cities
- Thousand Oaks, California • Fort Myers, Florida • Pensacola, Florida + 10 more
- Conditions
- Melanoma
- Interventions
- Blood Sample Collection
- Other
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Laguna Hills, California • Palm Springs, California + 32 more
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2005
- U.S. locations
- 26
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
- Conditions
- Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH)
- Interventions
- Dural Venous Sinus Stenting, Cerebrospinal Fluid Shunting
- Device
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Seattle, Washington
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Cisplatin, IMRT
- Drug · Radiation
- Lead sponsor
- Dan Zandberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Nohla Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acromegaly, Osteoporosis Risk
- Interventions
- Pegvisomant
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer
- Interventions
- cyclophosphamide, Cryoablation
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- BHQ880
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Interventions
- Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Cleveland, Ohio
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- AML, Adult, MDS
- Interventions
- Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA)
- Drug
- Lead sponsor
- Stelexis BioSciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Duarte, California • Aurora, Colorado • Tampa, Florida + 6 more
- Conditions
- Gastric Cancer
- Interventions
- Bemarituzumab, Placebo, Modified FOLFOX6
- Biological · Drug
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more
- Conditions
- Chronic Hepatitis B Infection
- Interventions
- ALG-000184, TDF
- Drug
- Lead sponsor
- Aligos Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Coronado, California • Pasadena, California • Rialto, California + 3 more
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, FLT3 Tyrosine Kinase Domain Point Mutation, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Decitabine, Laboratory Biomarker Analysis, Midostaurin
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, mitoxantrone hydrochloride, cytarabine, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- metformin hydrochloride, cytarabine, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Large B Cell Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 47
- States / cities
- La Jolla, California • Mountain View, California • Palo Alto, California + 38 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Sedona, Arizona + 23 more
- Conditions
- Colorectal Cancer
- Interventions
- 5-FU, Bevacizumab, Folinic acid, Oxaliplatin, Vanucizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 11 more
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
- Interventions
- questionnaire administration, survey administration, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee